Literature DB >> 20065848

Comparison between conventional surgery plus postoperative adjuvant radiotherapy and concurrent chemoradiation for FIGO stage IIB cervical carcinoma: a retrospective study.

Hideomi Yamashita1, Kae Okuma, Kei Kawana, Shunsuke Nakagawa, Katsutoshi Oda, Tetsu Yano, Shino Kobayashi, Reiko Wakui, Kuni Ohtomo, Keiichi Nakagawa.   

Abstract

OBJECTIVE: To compare treatment outcome of conventional surgery followed by adjuvant postoperative radiotherapy (PORT) versus concurrent chemoradiation therapy (cCRT) for stage IIB cervical carcinoma.
METHODS: A retrospective analysis was conducted of 59 patients with stage IIB uterine cervical cancer treated with radical surgery plus PORT (N = 34) or cCRT-alone (N = 25) from April 1996 to June 2008. The median follow-up time was 27 months (range, 3-150 months) in the cCRT group and 44 months (range, 4-134 months) in the PORT group. The median age was 59 years (range, 37-85 years) in the cCRT group and 49 years (range, 32-74 years) in the PORT group. All 34 patients in the surgery group underwent hysterectomy with pelvic lymph node dissection and received PORT. Twenty-five patients (42%) were assigned to the cCRT group.
RESULTS: The 3-year overall survival rates for surgery plus PORT and cCRT-alone were 80.0% and 75.1%, respectively. The difference between these 2 treatments was not statistically significant (log-rank P = 0.5871). The late complication rate of grade 3-4 was 12% in the cCRT group and 26% in the surgery group.
CONCLUSION: This retrospective study suggests that survival results with cCRT and with conventional surgery plus PORT for patients with stage IIB cervical carcinoma are comparable.

Entities:  

Mesh:

Year:  2010        PMID: 20065848     DOI: 10.1097/COC.0b013e3181cae5b7

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  14 in total

1.  Patterns of care in patients with cervical cancer 2012: results of a survey among German radiotherapy departments and out-patient health care centers.

Authors:  S Marnitz; C Köhler; A Rauer; A Schneider; V Budach; A Tsunoda; M Mangler
Journal:  Strahlenther Onkol       Date:  2013-07-27       Impact factor: 3.621

Review 2.  Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence.

Authors:  Shinya Matsuzaki; Maximilian Klar; Mikio Mikami; Muneaki Shimada; Brendan H Grubbs; Keiichi Fujiwara; Lynda D Roman; Koji Matsuo
Journal:  Curr Oncol Rep       Date:  2020-02-12       Impact factor: 5.075

Review 3.  Debulking hysterectomy followed by chemoradiotherapy versus chemoradiotherapy for FIGO stage (2019) IB3/II cervical cancer.

Authors:  Manas Chakrabarti; Andy Nordin; Juneida Khodabocus
Journal:  Cochrane Database Syst Rev       Date:  2022-09-16

4.  Aspects of Therapy for Cervical Cancer in Germany 2012 - Results from a Survey of German Gynaecological Hospitals.

Authors:  M Mangler; N Zech; A Schneider; C Köhler; S Marnitz
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-03       Impact factor: 2.915

5.  The Effect of Neoadjuvant Chemotherapy Combined With Brachytherapy Before Radical Hysterectomy on Stage IB2 and IIA Cervical Cancer: A Retrospective Analysis.

Authors:  Yun Dang; Qing Liu; Lixia Long; Hua Luan; Qingfang Shi; Xunyuan Tuo; Shumei Tuo; Yilin Li
Journal:  Front Oncol       Date:  2021-03-23       Impact factor: 6.244

6.  Nonadherence to Multimodality Cancer Treatment Guidelines in the United States.

Authors:  Leila T Tchelebi; Biyi Shen; Ming Wang; Louis Potters; Joseph Herman; Daniel Boffa; Joel E Segel; Henry S Park; Nicholas G Zaorsky
Journal:  Adv Radiat Oncol       Date:  2022-03-08

7.  Adjuvant chemotherapy, a valuable alternative option in selected patients with cervical cancer.

Authors:  Shuang Li; Ting Hu; Yile Chen; Hang Zhou; Xiong Li; Xiaodong Cheng; Ru Yang; Shixuan Wang; Xing Xie; Ding Ma
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

8.  Efficacy and toxicity of image-guided intensity-modulated radiation therapy combined with dose-escalated brachytherapy for stage IIB cervical cancer.

Authors:  Weiping Wang; Qingyu Meng; Xiaorong Hou; Xin Lian; Junfang Yan; Shuai Sun; Zhikai Liu; Zheng Miao; Dunhuang Wang; Xiaoliang Liu; Ke Hu; Fuquan Zhang
Journal:  Oncotarget       Date:  2017-11-15

9.  B3GNT3 Expression Is a Novel Marker Correlated with Pelvic Lymph Node Metastasis and Poor Clinical Outcome in Early-Stage Cervical Cancer.

Authors:  Weijing Zhang; Teng Hou; Chunhao Niu; Libing Song; Yanna Zhang
Journal:  PLoS One       Date:  2015-12-28       Impact factor: 3.240

10.  A Rare Case of Clear Cell Adenocarcinoma of the Cervix with No Intrauterine Diethylstilbestrol Exposure.

Authors:  Vinay Mathew Thomas; Swetha Ann Alexander; Matthew J Hadfield; James Vredenburgh
Journal:  Cureus       Date:  2020-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.